New triple therapy for tough lung cancer enters safety testing
NCT ID NCT05403723
First seen Feb 22, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This early-stage trial is testing whether adding a precise form of radiation (adaptive SBRT) to a standard immunotherapy-plus-chemotherapy regimen is safe for people with extensive-stage small cell lung cancer that has stopped responding to platinum chemo. About 50 participants will receive the combination and be monitored for side effects. The goal is to find a tolerable dose and see if the approach can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.